Background:
Background and Objective

Background:
 According to the American Diabetes Association, the annual cost of diabetes, which affects 25.8 million people in the U.S., was $245 billion in 2012 -$176 billion in direct medical costs and $69 billion in reduced workforce productivity 1, 2  One common complication of diabetes is the development of foot ulcers  Foot ulcers have been estimated to affect 1% to 6% of patients with diabetes annually and up to 25% of diabetes patients over their lifetime 3, 4  While diabetes patients with foot ulcers can require substantial amounts of resource use, little is known about the burden of these ulcers imposed on the U.S. healthcare system and payers
Objective:
 Estimate annual per-patient medical, prescription drug, and work-loss costs of diabetic foot ulcers (DFUs) using de-identified administrative claims data  For this purpose, DFU patients and non-DFU patients with diabetes (controls) were identified using two databases: ages 65+ from a 5% random sample of Medicare beneficiaries (Standard Analytical Files) and ages 1864 from a privately-insured population (OptumInsight)
Periods of Analysis
Diagnosis period
Patients with a DFU diagnosis during 20072011* were identified, with the date of each patient's most recent episode in this timeframe defined as the index date (the index date for the control group was randomly assigned to ensure similar timing distribution)
Follow-up period
Resource use and costs of treatment and control groups were compared for 12 months post-index to determine burden of illness Propensity score matching:
 To provide an unbiased estimation of the incremental costs due to DFU, DFU patients were matched to patients in the non-DFU diabetic control population using a "greedy" matching method based on: 
Medical costs
Inpatient and outpatient services comprised almost 75% of the cost differential for private insurance, with a more even distribution across places of service in Medicare * Includes use of nursing home care, skilled nursing facilities, rehabilitation centers, hospice, durable medical equipment, and some specialist services (e.g., chiropractor). 1. Estimated based on Type 2 diabetes population of 25.8 million and the midpoint (3.5%) of annual DFU incidence estimates. 1, 3, 4 Limitations:
 As with any claims data analysis, this analysis is based on ICD-9 and CPT codes to identify diagnoses and procedures as opposed to actual observance of medical conditions and resource use  Results may not generalize to other patient populations (e.g., Medicaid)
 Results potentially underestimate incremental burden due to factors such as:
 Costs not covered through Medicare (supplemental insurance)
 Excludes additional indirect costs (e.g., quality of life)
 Disproportionate removal of relatively high-cost DFU patients during the matching process
Conclusions:
 After accounting for differences in baseline characteristics, DFU patients had significantly higher medical resource use, resulting in them being approximately twice as expensive as the matched controls  The incremental annual cost of DFU is in the range of $10$15 billion, suggesting that presence of DFU imposes substantial burden on payers beyond that of care for diabetes alone  The study highlights the need for improved preventive measures and optimized treatment for DFUs to help avoid some severe and costly outcomes such as amputation
